IMMUNITYBIO, INC. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
IMMUNITYBIO, INC. (IBRX) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $2.03 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2019-05-08
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2019-03-31 was $2.03M, a 65.75% decline year-over-year.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2018-12-31 was $227.00K.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2018-09-30 was -$2.27M, a 154.51% decline year-over-year.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2018-06-30 was $774.00K, a 92.91% decline year-over-year.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2018 was $4.66M, a 50.91% decline from fiscal 2017.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2017 was $9.50M, a 245.08% increase from fiscal 2016.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2016 was $2.75M, a 502.41% increase from fiscal 2015.
- IMMUNITYBIO, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2015 was $457.00K.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2019-03-31 | $2.03M 10-Q · filed 2019-05-08 | $2.26M derived: sum of 2 quarters · filed 2019-05-08 | -$9.00K derived: sum of 3 quarters · filed 2019-05-08 | $765.00K derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$2.04M derived: sum of 2 quarters · filed 2019-03-13 | -$1.27M derived: sum of 3 quarters · filed 2019-03-13 | $4.66M 10-K · filed 2019-03-13 |
| 2018-09-30 | -$2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$1.49M derived: sum of 2 quarters · filed 2018-11-07 | $4.44M 10-Q · filed 2018-11-07 | -$3.62M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-06-30 | $774.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $6.70M 10-Q · filed 2018-08-06 | -$1.36M derived: sum of 3 quarters · filed 2019-05-08 | $2.80M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-03-31 | $5.93M 10-Q · filed 2019-05-08 | -$2.13M derived: sum of 2 quarters · filed 2019-05-08 | $2.03M derived: sum of 3 quarters · filed 2019-05-08 | $12.94M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | -$8.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$3.90M derived: sum of 2 quarters · filed 2019-03-13 | $7.01M derived: sum of 3 quarters · filed 2019-03-13 | $9.50M 10-K · filed 2019-03-13 |
| 2017-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $15.07M derived: sum of 2 quarters · filed 2018-11-07 | $17.56M 10-Q · filed 2018-11-07 | $19.22M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | $10.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $13.40M 10-Q · filed 2018-08-06 | $15.06M derived: sum of 3 quarters · filed 2019-03-13 | $14.10M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | $2.49M 10-Q · filed 2018-05-07 | $4.15M derived: sum of 2 quarters · filed 2019-03-13 | $3.19M derived: sum of 3 quarters · filed 2019-03-13 | $4.17M derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $694.00K derived: sum of 2 quarters · filed 2019-03-13 | $1.68M derived: sum of 3 quarters · filed 2019-03-13 | $2.75M 10-K · filed 2019-03-13 |
| 2016-09-30 | -$967.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $18.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.09M 10-Q · filed 2017-11-07 | $1.55M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $985.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $2.06M 10-Q · filed 2017-08-07 | $2.52M derived: sum of 3 quarters · filed 2018-03-12 | |
| 2016-03-31 | $1.07M 10-Q · filed 2017-05-08 | $1.53M derived: sum of 2 quarters · filed 2018-03-12 | ||
| 2015-12-31 | $457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $457.00K 10-K · filed 2018-03-12 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |